Shares of Innocare Pharma Limited (ASX: 09969) rose more than 5% during the trading session. At the time of writing, the stock was up 3.29% to HK$10.69, with a turnover of approximately HK$43.05 million.

The catalyst for the move was news released on June 18th. The company announced that the results from the global Phase III frontMIND study for its tafasitamab combination therapy were presented in an oral report at the plenary session of the 2026 European Hematology Association (EHA) Congress.

The findings demonstrated that, compared to the current first-line standard-of-care R-CHOP regimen, the combination of tafasitamab, lenalidomide, and R-CHOP (Tafa-Len-R-CHOP) showed a significant improvement in progression-free survival (PFS). The results were reported to be both statistically significant and of substantial clinical value.

This therapy holds the potential to offer a new first-line standard treatment option for patients with high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).